当前位置: 首页 > 期刊 > 《《中国医药学刊》》 > 2008年第5期
编号:11732744
三氧化二砷联合沙利度胺、地塞米松治疗老年初治Ⅲ期多发性骨髓瘤的临床研究(3)
http://www.100md.com 2008年5月1日 《中国医药学刊》 2008年第5期
     [8] Deaglio S,Canella D,Saj G,et a1.Evidence of an immunologic mechanism behind the therapeutical effects of arsenic trioxide on mye—loma cells.Leuk Res,2001,25:227—235.

    [9] Nikhil C. Munshi, M.D., Arsenic Trioxide:An Emerging Therapy for Multiple Myeloma The Oncologist, Vol. 6, Suppl 2, 17-21, April 2001.

    [10] Li, Xinquan; Ding, Xianzhong; Adrian, Thomas E Arsenic Trioxide Induces Apoptosis in Pancreatic Cancer Cells via Changes in Cell Cycle, Caspase Activation, and GADD Expression Pancreas. 2003,27(2):174-179.

    [11] Vacca A,Ribattti D,Presta M,et a1.Bone marrow neovascularization plasma cell angiogenic potential and matrix metallpproteinase-2 secretion paragression of human multiple myeloma [J].Blood,1999,93:3064.

    [12] 袁红,张晓梅,刘凯风,等.沙利度胺治疗多发性骨髓瘤的临床疗效[J].实用临床医药杂志,2006,10(5):35.

    [13] 张海燕,李玉芳,管滨,等.酞胺哌啶酮对恶性血液病患者血清肿瘤坏死因子受体的影响及临床意义[J].临床血液学杂志,2004, 7(5):261.

    [14] Davies F E,Rajenm H I,Deshim S T,et a1.Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma [J].Blood,2001,98:210.

    [15] 胡致平,林圣云,罗秀素,等. 三氧化二砷、沙利度胺和地塞米松联合治疗复发性、难治性多发性骨髓瘤[J]. 中国肿瘤,2007,16(2):131-133.

    [16] Palumbo A, Bertola A, Musto P, et al . A prospective randomized trial of oral melphalan,prednisone,thalidomide(MPT)vs oral melphalan , prednisone(MP):Blood,2004,104:63a., 百拇医药(宋 芹 芦济洲 李 健 李桂平 成 双)
上一页1 2 3